Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.66 |
| ▸ | PDE1A | P54750 | 3/20 | 0.66 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.66 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.66 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.66 |
| ▸ | PDE11A | Q9HCR9 | 3/20 | 0.66 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.66 |
| ▸ | PDE2A | O00408 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2698471 | 1.00 | MET (0.73) | METPDE3APDE1APDE4CPDE4D | |
| SCHEMBL4200183 | 1.00 | MET (0.73) | METPDE3APDE1APDE4CPDE4D | |
| SCHEMBL3599319 | 1.00 | MET (0.73) | METPDE3APDE1APDE4CPDE4D | |
| SCHEMBL3585934 | 0.87 | MET (0.74) | METPDE3APDE1APDE4CPDE4D | |
| SCHEMBL4195337 | 0.86 | MET (0.73) | METPDE3APDE1APDE4CPDE4D | |
| SCHEMBL10198801 | 0.86 | MET (0.73) | METPDE3APDE1APDE4CPDE4D | |
| SCHEMBL3594065 | 0.86 | MET (0.56) | METPDE3APDE1APDE4CPDE4D | |
| SCHEMBL14345664 | 0.84 | MET (0.77) | METPDE3APDE1APDE4CPDE4D | |
| SCHEMBL4201221 | 0.84 | MET (1.00) | METPDE3APDE1APDE4CPDE4D | |
| SCHEMBL14345674 | 0.84 | MET (0.70) | METPDE3APDE1APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231663-B1 | 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS | AMGEN INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3170824-A1 | 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS | Amgen, Inc (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-3093289-A1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR | Amgen, Inc (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9066954-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9066954-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009091374-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007138472-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885PDE3A 1765/4885PDE1A 3611/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885PDE3A 1765/4885PDE1A 3611/4885 |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885PDE3A 1765/4885PDE1A 3611/4885 |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | MAP4K5, MAPKAPK5, MAP4K2 | MET 1025/4885PDE3A 568/4885PDE1A 287/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885PDE3A 1765/4885PDE1A 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.